PCE Home Study
Maximizing the Benefits of Targeted Cancer Treatment With PI3K Inhibitors
Release Date: August 15, 2020
Expiration Date: August 14, 2021
CE/CME Credit Hours: 1.00
Pharmacology Credit Hours: 1.00
Begin »
program overview
Program Description
Significant advances in targeted and immunotherapies in recent years have revolutionized the treatment of cancer. Among the new therapeutic options are the phosphatidylinositol-3-kinase (PI3K) inhibitors, which have demonstrated efficacy in both hematologic malignancies and solid tumors, albeit at the price of a high risk of serious adverse effects. To date, the US Food and Drug Administration has approved four drugs in this class for treating cancer—alpelisib, copanlisib, duvelisib, and idelalisib. This online activity will focus on the role of PI3K in hematologic malignancies, the importance of PI3K inhibitors in treating these diseases, and methods of harnessing the therapeutic benefit of these drugs while minimizing and managing their toxicities.
Format
eNewsletter with interactive benchmarking
Learning Objectives
After completing this activity, participants should be better able to:
- Describe the mechanism of action of PI3K inhibitors and their place in the cancer-treatment paradigm
- Identify recommended strategies for management of adverse effects associated with PI3K inhibitors
- Implement measures, including patient education, to monitor for and manage adverse effects associated with PI3K inhibitors
Target Audience
Oncology NPs, PAs, and nurses
Faculty
Matthew S. Davids, MD, MMSc
- Assistant Professor of Medicine
- Harvard Medical School
- Director, DFCI Lymphoma Biobank
- Associate Director, CLL Center
- Dana-Farber Cancer Institute
- Boston, Massachusetts
Josie Montegaard, MSN, AGPCNP-BC
- Nurse Practitioner
- Dana-Farber Cancer Institute
- Boston, Massachusetts
Details
Joint Accreditation Statement
In support of improving patient care, Practicing Clinicians Exchange is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.
ANCC Credit Designation
Nursing contact hours: 1.00, which includes 1.00 hour of pharmacology credit
AAPA Credit Designation
Practicing Clinicians Exchange has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.00 AAPA Category 1 CME credit. Approval is valid until August 14, 2021. PAs should only claim credit commensurate with the extent of their participation.
PA course advisor: Corinne Williams, PA-C, Northwestern University Feinberg School of Medicine, Chicago, Illinois
IPCE Credit Designation
This activity was planned by and for the healthcare team, and learners will receive 1.00 Interprofessional Continuing Education (IPCE) credit for learning and change.
This program was developed from a series of programs cosupported by educational grants from Astellas; Astellas and Pfizer; Celgene Corporation; Exelixis; GlaxoSmithKline; Karyopharm Therapeutics; Merck & Co., Inc.; Pharmacyclics LLC, an AbbVie Company; Sanofi Genzyme; Seattle Genetics; and Verastem Oncology.
This activity is supported by an educational grant from Verastem Oncology.
The opinions or views expressed in this CE/CME activity do not necessarily reflect the opinions or recommendations of Practicing Clinicians Exchange or any educational supporter.
All faculty and planners participating in continuing education activities sponsored by Practicing Clinicians Exchange are required to disclose to the audience any relevant support or substantial relationships with providers of commercial products and/or devices discussed in this activity and/or with any commercial supporters of the activity. In addition, all faculty are required to openly disclose any off-label, experimental, or investigational use of drugs or devices discussed in this activity. The faculty and planning committee have been advised that this activity must be free from commercial bias, and based upon all the available scientifically rigorous data from research that conforms to accepted standards of experimental design, data collection, and analysis.
Dr Davids: consultant: Adaptive Biotechnologies, Beigene, Celgene, Janssen, Research to Practice, Zentalis; consultant/research support: AbbVie, Ascentage Pharmaceuticals, AstraZeneca, Genentech, MEI Pharmaceuticals, Pharmacyclics, TG Therapeutics, Verastem; research support: Surface Oncology.
Ms Montegaard: advisory board: AstraZeneca, Pharmacyclics; expert panel: Janssen.
Ms Williams: speakers bureau: AstraZeneca.
None of the members of the PCE staff have any relevant relationships to disclose.
Participants wishing to earn CE/CME credit must:
- Read the content in its entirety
- Relate the content material to the learning objectives
- Complete the post-test and evaluation form
Successful completion of the post-test is required to earn CE/CME credit. Successful completion is defined as a cumulative score of at least 70%.
Release date: August 15, 2020
Expiration date: August 14, 2021
For Practicing Clinicians Exchange general information, contact pce@practicingclinicians.com.
© 2021 Practicing Clinicians Exchange. All Rights Reserved. 97520OPCE-7G